David P. Wood, Jr., MD gave a presentation at the 9th International Prostate Forum (IPF) on October 8 - 10, 2009 in Izmir, Turkey on the Management the side effects of hormone therapy (ADT) when used to treat of prostate cancer. Dr. Wood indicated that the three major side effects of ADT in the treatment [...]
The relatively new drug, denosumab, has proven itself very effective for men on a hormone blockade (ADT). In a recently completed 3-year, randomized, double-blind study at the Massachusetts General Hospital Cancer Center, Boston, Massachusetts, denosumab significantly increased bone mineral density and decreased new vertebral fractures in men receiving ADT for the treatment of advanced prostate [...]
A study from Milan Italy look at the controversy, does the testosterone level achieved with androgen-deprivation therapy (ADT) increase the survival in men with metastatic prostate cancer? ADT comes with significant morbidity issues, so is there an adequate benefit from ADT (does it provide survival benefits) to balance out the negative side effects? This [...]
Advanced prostate cancer will progress and most of us will face a time when Androgen Deprivation Therapy (ADT) stops working. Most men on ADT take a LHRH agonist, which turns off the production of testosterone (i.e. Lupron) along with a non-steroidal anti-androgen (i.e. Casodex) that prevents the small amount of testosterone that continues to be [...]
It is inevitable; most men with prostate cancer, who require treatment with androgen deprivation therapy (ADT), will eventually become resistance to treatment leading to the development of metastatic disease. Men who develop metastatic castrate-resistant disease have a very poor prognosis. Historically, their overall survival is estimated only to be 24 to 36 months. A study [...]
In a small trial using oral sodium clodronate, a bisphosphonate like Zometa and Fosamax, it was shown to extended prostate cancer survival by 23 percent (23%). The survival benefit was seen only when the drug was used in combination with hormone therapy in men with metastatic disease. Many doctors have believed that bisphosphonates could have [...]
Combined androgen blockade with bicalutamide for advanced prostate cancer: Long-term follow-up of a phase 3, double-blind, randomized study for survival Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan has released some very significant survival data about a previously reported, double-blind, randomized, multicenter phase 3 trial. This trial compared combined androgen blockade [...]
I have written a fair amount over the life of this blog about the cognitive impairment that many of us experience when we are on an androgen blockade (ADT). I have share my experiences about getting lost on the NYC subway, forgetting where I was going and why I was going there. I also have [...]
So how long does it usually take for men undergoing hormone therapy (ADT) to progress from being hormone dependent to hormone independent? Clearly, we should always remember that this is a very individual, case-by-case time. However, there was a recent time analysis published in the February 2009 edition of Urology. These researchers found that after [...]
The Department of Urology, University of Tennessee Health Science Center, Memphis, TN, performed a retrospective study designed to evaluate the overall survival (OS) and disease-specific survival (DSS) in men receiving primary androgen-deprivation therapy (PADT) or salvage medical ADT (SADT) for prostate cancer. The study included men who were diagnosed and treated with ADT between July [...]
